After last week’s big moves across the global financial markets, the FED and geopolitics will be in focus along with a sprinkle of economic data…
from Yahoo Finance https://ift.tt/3gY91GJ
Equities exploded higher, with the Nasdaq Composite hitting a record high, as a better-than-expected labor report sent stocks higher. With that in mind, let's look a few top stock trades for next week. Top Stock Trades for Monday No. 1: Slack (WORK) Click to EnlargeSource: Chart courtesy of StockCharts.comSlack (NYSE:WORK) stock is getting hammered on Friday, down more than 14% after disappointing quarterly results. However, shares declined right down into potential support.The $30 to $30.50 area was multi-month resistance, keeping a lid on WORK as bulls continued to bid it higher. On Friday's gap down, though, Slack found buyers just before this level was hit — pushing it back up toward $33.InvestorPlace – Stock Market News, Stock Advice & Trading TipsNext week, bulls have a big task ahead of them. They need to build on Friday's momentum off the lows, preferably pushing shares back above the 20-day moving average. If it can, it will begin to fill back into the gap. * 7 Hotel Stocks to Buy Before Vacationing Restarts On the downside, however, see how Slack handles the 50-day moving average should shares break below $30. Top Stock Trades for Monday No. 2: Nvidia (NVDA) Click to EnlargeSource: Chart courtesy of StockCharts.comI made a point earlier, highlighting how Nvidia (NASDAQ:NVDA) has been sluggish since reporting earnings. That said, though, the bears haven't been able to crack this stock — which rallied hard into earnings before reporting a solid result.It has continued to hold the 10-day moving average over the past week, as shares work on pushing over $355.This setup is simple. Over $355, and $360 is in play. Once we get to next week, look to see if Nvidia can go "weekly up" by rotating over this week's high (currently at $359.88). A move over that could put the all-time highs near $367 in play.On a break of the 10-day moving average, though, see how Nvidia does on a test of the 20-day moving average and uptrend support (blue line). Below puts $310 and the recent low near $320 in play. Top Stock Trades for Monday No. 3: Royal Caribbean (RCL) Click to EnlargeSource: Chart courtesy of StockCharts.comThe "reopening America" trades have been red hot, and cruises aren't missing out on the action. Royal Caribbean (NYSE:RCL) is among the group, up more than 20% on Friday alone.In late May, RCL stock broke out over multi-month resistance near $50, then held this level as support. After several days of consolidation, RCL exploded higher on Friday — reclaiming its declining 100-day moving average amid the move. * 3 Chinese Stocks to Buy As Emerging Markets Heat Up Bulls will now want to see this level hold as support. On the upside, see if Royal Caribbean can extend up into the $75 to $80 zone where it finds the 50% retracement and resistance from March. Above puts the 200-day moving average in play. Top Stock Trades for Monday No. 4: Carnival Cruise (CCL) Click to EnlargeSource: Chart courtesy of StockCharts.comCarnival Cruise (NYSE:CCL) is also performing well, ending the day Friday up more than 16%. However, the stock has not been trading as well as RCL.That said, after a solid double-bottom in March and April, shares put in a higher low before breaking out over resistance near $18. Now after gapping higher on Friday, CCL faces a tall task.Shares face the 38.2% retracement, declining 100-day moving average and a big gap between $24.50 and $27. Above that, and the 200-day moving average is a possible upside target. But if I've been long this name, I'd be trimming a bit into this strength.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVDA. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * Top Stock Picker Reveals His Next 1,000% Winner * The 1 Stock All Retirees Must Own * Look What America's Richest Family Is Investing in Now The post 4 Top Stock Trades for Monday: WORK, NVDA, RCL, CCL appeared first on InvestorPlace.
from Yahoo Finance https://ift.tt/2Yc5Nqb
In this article you are going to find out whether hedge funds think Bed Bath & Beyond Inc. (NASDAQ:BBBY) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the […]
from Yahoo Finance https://ift.tt/2XCj2Sa
If there's one thing that traders have learned about Inovio Pharmaceuticals (NASDAQ:INO) stock, it's that half a year can make a huge difference. Biotechnology stocks can be fast movers, sure, but this particular one has been a real barn burner, as they say.Source: Ascannio / Shutterstock.com INO stock was trading for $3 and change at the beginning of this year, but a whole lot has happened since then. The spread of the novel coronavirus has put clinical-stage biotechnology companies like Inovio in the spotlight. And that's enriched its stockholders while causing problems for short sellers.The share price did ease off of the mid-May peak, but that's not necessarily indicative of any actual problems with Inovio. For those traders who did choose to take profits on INO stock, they may soon find that they cut their winnings short and left a considerable amount of money on the table.InvestorPlace – Stock Market News, Stock Advice & Trading Tips A Serious ContenderThe race to develop a vaccine for the coronavirus is still in effect and it's closely watched by the investing community. Each stage of progress in the development of a vaccine is likely to be rewarded by stock traders.Among the contenders in the biotechnology space, Inovio is a strong candidate. It is working tirelessly in pursuit of the elusive coronavirus vaccine. A recent research study suggested potentially positive results for Inovio's Covid-19 vaccine candidate, INO-4800. In this study, the vaccine candidate was tested on laboratory mice and guinea pigs.Those preliminary findings aren't the be-all and end-all, but they represent great progress for Inovio. By the end of this year, the company plans to have 1 million doses of INO-4800. It's conceivable that Inovio could become a household name in 2020. * 7 Hotel Stocks to Buy Before Vacationing Restarts And a high-figure financial award could help Inovio's plans come to fruition. Specifically, the Coalition for Epidemic Preparedness Innovations has given Inovio a total of $17.2 million. That's a tremendous head start from a financial standpoint. A Promising PartnershipHaving access to the capital provided by the Coalition for Epidemic Preparedness Innovations will undoubtedly prove to be advantageous for Inovio. But a game-changing partnership between research-driven entities could give Inovio an even greater edge over the competition.On June 4, the International Vaccine Institute and Seoul National University Hospital announced a headline-grabbing collaboration. Together, they will commence a Phase 1/2 clinical trial of INO-4800 in South Korea.This event is already making history as this two-stage trial, which is scheduled to begin later in June, will be the first Covid-19 vaccine clinical study in Korea. At first, INO-4800 will be tested on 40 healthy adults ranging in age from 19 to 50 years.After that, 120 more people, ranging in age from 19 to 64 years, will be enrolled in the study. Funding for this research will come from the Coalition for Epidemic Preparedness Innovations with support from the Korea Center for Disease Control and Prevention/Korea National Institute of Health.This is an excellent example of fast-tracking in action. Usually it would take several years to begin clinical trials for a new vaccine. But since the need for a coronavirus vaccine is urgent, this INO-4800 study can start promptly.International Vaccine Institute Director General Jerome Kim expressed eagerness to move forward with the trial. He called the INO-4800 research "a crucial step in the development of an urgently needed COVID-19 vaccine."Seoul National University Hospital Professor Myung Don Oh also emphasized the importance of the upcoming INO-4800 trial. He predicted that the trial "will provide significant momentum in easing fears over the pandemic and helping return to normalcy." The Final Word on INO StockThe prospect of INO-4800 helping get the world get back to a more normal, healthy state is encouraging. INO stockholders should be encouraged by Inovio's efforts to be first to market with a coronavirus vaccine. And they can view any share-price dips as temporary as the company's progress should be reflected in the stock price soon enough.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * Top Stock Picker Reveals His Next 1,000% Winner * The 1 Stock All Retirees Must Own * Look What America's Richest Family Is Investing in Now The post Why You Shouldn't Rush to Take Profits on Inovio Stock appeared first on InvestorPlace.
from Yahoo Finance https://ift.tt/3h4Gf72

Over the last 30 years the Australian share market has provided investors with an average total return of ~9.5% per annum. This is roughly in line with what the U.S. share market has achieved historically.
It is worth remembering that this is the average, which means some shares outperformed and others underperformed.
This also means that the more shares you have in your portfolio that outperform, the better your chances of beating the market.
But which shares could beat the market in the future? While picking outperformers over three decades is probably impossible, I think a decade is possible.
Three ASX shares that I think have the potential to be market beaters throughout the 2020s are listed below. Here’s why I rate them highly:
The first future market beater could be Appen. It is a leading developer of high-quality, human annotated datasets for machine learning and artificial intelligence models. It provides its services to many of the world’s biggest tech giants including Facebook and Microsoft. I believe this is a testament to the quality of its offering. And with demand for these services expected to continue to grow at a strong rate due to the increasing importance of artificial intelligence, I believe the future is very bright for Appen.
Another ASX share which I think could beat the market over the long term is NEXTDC. It is a data centre operator with a portfolio of world class centres in key locations across Australia. The company has been experiencing significant and growing demand for its services over the last couple of years. This has been driven by the shift to the cloud and the ever-increasing amount of data being generated by consumers and businesses. I expect more of the same over the next decade as the shift to the cloud accelerates.
Finally, I think this sleep treatment-focused medical device company’s shares could beat the market during the 2020s. This is thanks to ResMed’s market-leading products and massive market opportunity. Management estimates that only ~20% of sleep apnoea sufferers have been diagnosed. Given the growing awareness of the sleep disorder, I believe more diagnoses to be made in the coming years. I expect this to underpin strong earnings growth for the foreseeable future.
And here are more top shares which could provide strong long term returns…
NEW! 5 Cheap Stocks With Massive Upside Potential
Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.
One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…
Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.
Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.
Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.
But you will have to hurry because the cheap share prices on offer today might not last for long.
As of 2/6/2020
More reading
Motley Fool contributor James Mickleboro owns shares of NEXTDC Limited. The Motley Fool Australia owns shares of Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Could these sensational ASX shares help you beat the market? appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/37aqpDj
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
from Yahoo Finance https://ift.tt/3dG94Vv
(Bloomberg Opinion) — Saudi Arabia called out the cheats at yesterday’s OPEC meeting — the countries that hadn’t fully reduced oil output in May as agreed — and extracted promises that they would compensate with even deeper reductions in the third quarter. Now the kingdom faces the group’s perennial problem of enforcing those promises.The meetings of the Organization of Petroleum Exporting Countries and the bigger OPEC+ group, which includes Russia and nine other countries, were the shortest and least controversial since the latter collective was formed in 2016. It’s not that there was no drama; it just all took place in the days before the virtual gatherings.The drama centered around the failure of key countries to make all the output cuts they had promised when the group met by videoconference the previous month. Of the 20 countries participating in that deal, 19 agreed to reduce their production by 23% from agreed-upon baselines. Only Mexico held out, and eventually the others gave in to its demand for a smaller reduction.When the May production estimates started coming in, however, it became abundantly clear that several countries hadn’t fulfilled their promises. That’s not unusual — but what followed was.Saudi Arabia was done turning a blind eye to the cheats. It spent a week threatening and cajoling them. In the end, as well as agreeing to extend current output targets through July, the other countries promised to compensate for the barrels they failed to remove in May, and would fail to cut in June, by making deeper cuts in the third quarter.Four countries, in particular, were held to account — Iraq, Nigeria, Angola and Kazakhstan. Iraq and Nigeria have long histories of failing to make the cuts they promised under previous OPEC+ agreements. Angola’s production last year was well below its target, and Kazakhstan met its obligations on average over the period, thanks to maintenance and unexpected outages at its biggest oil fields. But neither cut quite as much as they had pledged last month.Iraq especially angered the Saudis by admitting that, not only had it failed to meet its obligations in May, but it wouldn’t be able to get output down to its target level until the end of July. On the other hand, Nigeria had insisted that its production numbers were reported incorrectly by the secondary sources that OPEC relies on to monitor production, but its oil minister eventually admitted in an Instagram post that the country had cut production by 216,000 barrels a day — 52% of the reduction it had promised.All four countries eventually agreed to the principle of making additional compensatory output cuts in the coming months. The real tests will be whether they do, and how Saudi Arabia reacts if they don’t.Back in March, when Russia refused to accept deeper output cuts championed by Saudi Arabia, the kingdom threatened to bring the whole OPEC+ edifice crashing down, rather than go on without Russia’s full participation. Russia called Riyadh’s bluff, and the Saudis proceeded to boost their oil production to more than 12 million barrels a day in early April — just as the destruction of global oil demand by the Covid-19 pandemic reached its peak.The kingdom seems to have threatened to do the same again, if it didn’t get its way ahead of Saturday’s meetings. But Iraq and Nigeria learned from Moscow’s mistake — at least well enough to say the right things to appease Saudi Arabia.Nigeria may be able to meet the new goal, as it will be aided in the task: Maintenance being conducted on at least one of its major offshore oil fields means production will run at reduced rates and shut down completely for several days. Iraq, though, will find it more difficult. In fact, I don’t see any way that it can meet its obligations by the end of September.Assuming its production falls steadily between now and the end of July to reach its target level, Iraq would still have to reduce output in August and September by more than 1.3 million barrels a day from what it pumped in April — taking production down to a level not seen in six years. That is going to be a very tough sell for the newly installed government in Baghdad.OPEC and OPEC+ only have more promises from those countries to make deeper cuts. The organizations have no mechanisms to enforce them.But after the disastrous meetings in March and April, Saudi Arabia looked strong in the run-up to Saturday’s gathering, holding Iraq and Nigeria to account. Maybe those countries will find a way to do what they’ve promised. But even if they don’t, it might not matter so much. Because by demanding extra cuts and getting promises that they will come, the Saudi oil minister has sent a warning to other would-be backsliders: They, too, will be called out if they fall short.Plus, the oil market could look very different by July. Brent crude is already above $40 a barrel, demand is slowly recovering and supply has been reduced significantly. They may be able to meet their promises simply by maintaining cuts while others slowly increase output.For now, Saudi Arabia has shown that it can exercise a degree of authority over the other OPEC members and instill some discipline, or promises of it. Even that is a big step toward restoring credibility to OPEC and OPEC+ after a couple of bruising meetings earlier this year.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Julian Lee is an oil strategist for Bloomberg. Previously he worked as a senior analyst at the Centre for Global Energy Studies.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/37bWPh4

Right now, I believe that are a number of small cap ASX shares that have the potential to grow into much larger entities in the future.
Three small cap shares which I feel would be worth keeping a close eye on are listed below. Here’s why I like them:
The first small cap ASX share to watch is Alcidion. It is a healthcare informatics solutions company which provides software that improves the efficacy and cost of delivering services to patients. Its software also helps to reduce hospital-acquired complications, which can ultimately save lives. I believe Alcidion is well-positioned for growth thanks to the trend for healthcare organisations to shift to a paperless environment. And while the pandemic could stifle its near term growth, I remain confident in its long term outlook.
A second small cap ASX share to watch is Medadvisor. It is a healthcare technology company which is focused on personal medication adherence. Medadvisor’s app connects to pharmacy dispensing systems to automatically retrieve medication records and drive an intelligent training, information, and reminder system. This has been designed to ensure correct and reliable medication use. Another product which I feel has a lot of potential is its telehealth solution. This allows patients to attend GP consultations from the comfort of their own home.
A final small cap share to watch is Serko. It is a technology company focused on corporate travel and expense management. It was growing at a very strong rate prior to the pandemic. This was driven partly by the increasing demand for its Zeno product. Zeno revolutionises the world of online travel booking technology and expense management. Demand for its services will inevitably be impacted by the current crisis, but I expect it to bounce back strongly once conditions ease.
And here are more top shares to consider. All five recommendations below look very cheap right now…
NEW! 5 Cheap Stocks With Massive Upside Potential
Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.
One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…
Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.
Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.
Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.
But you will have to hurry because the cheap share prices on offer today might not last for long.
As of 2/6/2020
More reading
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd, MedAdvisor, and Serko Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd, MedAdvisor, and Serko Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 3 exciting small cap ASX shares to watch very closely appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2UhBJbO
It's natural to wish that you had taken a stake in Nio (NYSE:NIO) when Nio stock was trading at $2 and change this year. That's a phenomenon you could call "hindsight investing," where a great stock trade is obvious only after the fact.Source: Sundry Photography / Shutterstock.com Nio stock is higher than $2 now, of course, and that raises the question of whether it can go much higher. Should value-focused investors avoid a particular stock just because it recently doubled in value? The thoroughly unsatisfying answer is: it depends on the stock and the circumstances.Based on the data, there should be plenty of upside left for Nio stock. In fact, it's entirely possible that the shares could double again from here. After all, this was a $10 stock a year and a half ago. Could it get there again before the year is over?InvestorPlace – Stock Market News, Stock Advice & Trading Tips * 7 Hotel Stocks to Buy Before Vacationing Restarts When Flat Is All You Could Ask forBetween the havoc caused to automotive supply chains in China and the demand destruction in terms of new-vehicle sales, the novel coronavirus is quite possibly the worst thing that could have happened to Nio and its shareholders.All things considered, though, an argument could be made that the company is taking the Covid-19 mayhem in stride. Or at the very least, the damage control has been adequate.This is reflected in the price action of Nio stock, which is working its way back up to the 52-week high of about $6. Besides, there's a glimmer of hope on the horizon for the Chinese automotive market, and hence for Nio.As Baird analyst David Leiker points out, automotive production in China cratered by 44% during this year's first quarter. There was a bounce-back in April, however, as nationwide production was flat for that month on a year-over-year basis.Amid the backdrop of a viral pandemic, flat is pretty darned good. The airlines and the cruise-ship companies would gladly take flat over their current conditions. And China is still the world's largest electric-car market, so Nio's got a big, albeit weather-beaten, playground to play in. A Realistic ReboundWhen it comes to the automotive market, investors would be better off keeping their expectations low. If you're hoping for a tremendous rebound in the current market conditions, you're only setting yourself up for a major disappointment.Nio's first-quarter financial results paint a picture of a company in distress but starting to regain its footing. For instance, the company delivered 3,838 cars during that quarter. That's not too different from the 3,989 vehicles that Nio delivered during the same quarter of the previous year, long before the coronavirus craziness commenced.Moreover, the quarterly sales figure topped the analyst community's expectations. On average, they were projecting $180 million in quarterly sales for Nio. The actual result was roughly $194 million. So, add another one to the win column for Nio.Plus, we have to bear in mind the timeline of the coronavirus's spread in China, which peaked earlier than it did in the United States. China's financial struggles accelerated mainly during that first quarter. Against this backdrop, Nio's not-too-awful quarter was really quite impressive.And if we shift our scrutiny to April, which wasn't included in the first-quarter financial results, the overall picture really starts to brighten. Believe it or not, in April, Nio managed to deliver 3,155 vehicles. To give you some context on that figure, it's more than twice March's deliveries.It's also an improvement of more than 180% compared to Nio's deliveries in April of last year. Looking ahead now to the second quarter, Nio expects to deliver around 9,750 cars in that time frame.Summing up his evident relief, Nio CEO William Bin Li observed, "We have witnessed the order growth to have rebounded to the level prior to the Covid-19 outbreak since late April." The Takeaway on Nio StockAppreciating how "flat" can be really good isn't something that every investor's willing to do.If you're willing to take a data-backed leap of faith, however, then a long position in Nio stock could reward your tempered optimism in the long run.David Moadel has provided compelling content – and crossed the occasional line – on behalf of Crush the Street, Market Realist, TalkMarkets, Finom Group, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * Top Stock Picker Reveals His Next 1,000% Winner * The 1 Stock All Retirees Must Own * Look What America's Richest Family Is Investing in Now The post You Haven't (Yet) Missed the Nio Opportunity appeared first on InvestorPlace.
from Yahoo Finance https://ift.tt/2BGv4l0